Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash & Equivalents (2016 - 2025)

Agios Pharmaceuticals' Cash & Equivalents history spans 14 years, with the latest figure at $89.1 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 16.9% year-over-year to $89.1 million; the TTM value through Dec 2025 reached $89.1 million, up 16.9%, while the annual FY2025 figure was $89.1 million, 16.9% up from the prior year.
  • Cash & Equivalents reached $89.1 million in Q4 2025 per AGIO's latest filing, down from $92.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $1.9 billion in Q1 2021 to a low of $64.3 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $255.4 million, with a median of $90.9 million recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 2019.16% in 2021, then tumbled 95.76% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $203.1 million in 2021, then tumbled by 31.44% to $139.3 million in 2022, then plummeted by 36.66% to $88.2 million in 2023, then dropped by 13.56% to $76.2 million in 2024, then increased by 16.9% to $89.1 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Cash & Equivalents are $89.1 million (Q4 2025), $92.7 million (Q3 2025), and $80.9 million (Q2 2025).